Treatment of diabetes mellitus in dialysis patients


Cite item

Full Text

Abstract

Diabetes mellitus is a key cause of chronic kidney disease (CKD) in developed contries. Disorders of glucose metabolism regulation in CKD are explained by insulin resistance, decreased insulin clearance, weak hormonal response to hypoglycemia. These disturbances appear in inhibition of glomerular filtration rate under 60 ml/min. Hemodialysis treatment raises the risk of hypoglycemic conditions due to glucose elimination from blood circulation during the sessions and improvement of sensitivity to insulin. Use of glucose-containing solutions for dialysis, step-by-step achievement of normoglycemia, monitoring of blood glucose during dialysis sessions are recommended for reducing the risk of hypoglycemic conditions in DM patients on dialysis. Insulin is the most common preparation in the treatment with use of hemodialysis in diabetics. Tiasolidindions (pioglitason, rosiglitason) and analogues of dipeptidilpeptidase of type IV (sitagliptin, saxagliptin) can be administered in type 2 diabetics without insulin insufficiency. As solutions for peritoneal dialysis contain glucose, such dialysis may entail such metabolic complications as fat accumulation, metabolic syndrome. Intraperitoneal introduction of insulin allows avoiding hyperinsulinemia and in some cases to decrease the risk of hypoglycemia. Side effects of intraperitoneal insulin administration are significant absorption of insulin on the surface of the systems for intraperitoneal dialysis, higher rate of peritonitis, subcapsular hepatic steatosis. In the absence of controlled studies the mode of insulin administration in patients on peritoneal dialysis should be chosen individually basing on potential risk and benefit for the patient and experience of the dialysis center. It should be remembered that adequate sugar-reducing treatment is necessary for prevention of complications and prolongation of survival of diabetics on dialysis.

About the authors

Irina Arkad'evna Bondar'

Vadim Valer'evich Klimontov

Email: klimontov@mail.ru

I A Bondar

State Medical University, Novosibirsk

State Medical University, Novosibirsk

V V Klimontov

State Medical University, Novosibirsk

State Medical University, Novosibirsk

References

  1. Schemthaner G. Kidney disease in diabetology: lessons from 2007. Nephrol. Dial. Transplant. 2008; 23 (4): 1112-1115.
  2. Rossing P. The changing epidemiology of diabetic microangiopathy in type 1 diabetes. Diabetologia 2005; 48 (8): 1439- 1444.
  3. van Dijk P. С. W., Jager K. J., Stengel B. et al. Renal replacement therapy for diabetic end-stage renal disease: data from 10 registeries in Europe (1991-2000). Kidney Int. 2005; 67 (4): 1489-1499.
  4. Бикбов Б. Т., Томилина Н. А. Состояние заместительной почечной терапии больных с хронической почечной недостаточностью в Российской Федерации в 1998-2007 гг. (Аналитический отчет по данным Российского регистра заместительной почечной терапии). Нефрология и диализ 2009; 3: 144-219.
  5. Sechi L. A., Catena С., Zingaro L. et al. Abnormalities of glucose metabolism in patients with early renal failure. Diabetes 2002; 51 (4): 1226-1232.
  6. Kobayashi S., Maesato K., Moriya H. et al. Insulin resistance in patients with chronic kidney disease. Am. J. Kidney Dis. 2005; 45 (2): 275-280.
  7. Charlesworth J. A., Kriketos A. D., Jones J. E. et al. Insulin resistance and postprandial triglyceride levels in primary renal disease. Metabolism 2005; 54 (6): 821-828.
  8. Rave K., Heise Т., Pfützner A. et al. Impact of diabetic nephropathy on pharmacodynamic and pharmacokinetic properties of insulin in type 1 diabetic patients. Diabet. Care 2001; 24 (5): 886-890.
  9. D'Apolito M., Du X., Zong H. et al. Urea-induced ROS generation causes insulin resistance in mice with chronic renal failure. J. Clin. Invest. 2010; 120 (1): 203-213.
  10. Бергер М., Старостина Е. Г., Йоргенс В., Дедов И. Практика инсулинотерапии. 1-е рус. изд. Berlin; Heidelberg: Springer-Verlag; 1990.
  11. Moen M. F., Zhan M., Hsu V. D. et al. Frequency of hypoglycemia and its significance in chronic kidney disease. Clin. J. Am. Soc. Nephrol. 2009; 4 (6): 1121-1127.
  12. Климонтов В. В. Особенности формирования и ранняя диагностика почек у больных сахарным диабетом 1-го типа: Автореф. дис. ... д-ра мед. наук. Новосибирск; 2008.
  13. Burger A. J., D'Elia J. A., Weinrauch L. A. et al. Marked abnormalities in heart rate variability are associated with progressive deterioration of renal function in type I diabetic patients with overt nephropathy. Int. J. Cardiol. 2002; 86 (2-3): 281- 287.
  14. Abe M., Kikuchi F., Kaizu K., Matsumoto K. The influence of hemodialysis membranes on the plasma insulin level of diabetic patients on maintenance hemodialysis. Clin. Nephrol. 2008; 69 (5): 354-360.
  15. Abe M., Kaizu K., Matsumoto K. Plasma insulin is removed by hemodialysis: evaluation of the relation between plasma insulin and glucose by using a dialysate with or without glucose. Ther. Apher. Dial. 2007; 11 (4): 280-287.
  16. Foss M. C., Gouveia L. M., Moysés Neto M. et al. Effect of hemodialysis on peripheral glucose metabolism of patients with chronic renal failure. Nephron 1996; 73 (1): 48-53.
  17. Даугирдас Дж. Т., Блэйк П. Дж.., Инг Т. С. Руководство по диализу: Пер. с англ. 3-е изд. М.: Центр диализа; Тверь: ООО Изд-во "Триада"; 2003.
  18. Шестакова М. В., Дедов И. И. Сахарный диабет и хроническая болезнь почек. - М.: Мед. информ. агентство; 2009.
  19. Tascona D. J., Morton A. R., Toffelmire Е. В. et al. Adequacy of glycemic control in hemodialysis patients with diabetes. Diabet. Care 2006; 29 (10): 2247-2251.
  20. Oomichi Т., Emoto M., Tabata T. et al. Impact of glycemic control on survival of diabetic patients on chronic regular hemodialysis: a 7-year observational study. Diabet. Care 2006; 29 (7): 1496-1500.
  21. Fukuoka K., Nakao K., Morimoto H. et al. Glycated albumin levels predict long-term survival in diabetic patients undergoing haemodialysis. Nephrology (Carlton) 2008; 13 (4): 278-283.
  22. Ishimura E., Okuno S., Kono K. et al. Glycemic control and survival of diabetic hemodialysis patients - importance of lower hemoglobin A1C levels. Diabet. Res. Clin. Pract. 2009; 83 (3): 320-326.
  23. Shrishrimal K., Hart P., Michota F. Managing diabetes in hemodialysis patients: observations and recommendations. Cleveland. Clin. J. Med. 2009; 76 (11): 649-655.
  24. Manley H. J., Allcock N. M. Thiazolidinedione safety and efficacy in ambulatory patients receiving hemodialysis. Pharmacotherapy 2003; 23 (7): 861-865.
  25. Chiang С. K., Но Т. I., Peng Y. S. et al. Rosiglitazone in diabetes control in hemodialysis patients with and without viral hepatitis infection: effectiveness and side effects. Diabet. Care 2007; 30 (1): 3-7.
  26. Abe M., Kikuchi F., Kaizu K., Matsumoto K. Combination therapy of pioglitazone with voglibose improves glycemic control safely and rapidly in Japanese type 2-diabetic patients on hemodialysis. Clin. Nephrol. 2007; 68 (5): 287-294.
  27. Brunelli S. M., Thadhani R., Ikizler T. A., Feldman H. I. Thiazolidinedione use is associated with better survival in hemodialysis patients with non-insulin dependent diabetes. Kidney Int. 2009; 75 (9): 961-968.
  28. Sobngwi E., Enoru S., Ashuntantang G. et al. Day-to-day variation of insulin requirements of patients with type 2 diabetes and end-stage renal disease undergoing maintenance hemodialysis. Diabet. Care 2010; In press.
  29. Jackson M. A., Holland M. R., Nicholas J. et al. Hemodialysis-induced hypoglycemia in diabetic patients. Clin. Nephrol. 2000; 54 (1): 30-34.
  30. Burmeister J. E., Scapini A., da Rosa Miltersteiner D. et al. Glucose-added dialysis fluid prevents asymptomatic hypoglycaemia in regular haemodialysis. Nephrol. Dial. Transplant. 2007; 22 (4): 1184-1189.
  31. Rohrscheib M., Tzamaloukas A. H., Ing T. S. et al. Serum potassium concentration in hyperglycemia of chronic dialysis. Adv. Perit. Dial. 2005; 21: 102-105.
  32. Cho K. H., Do J. Y., Park J. W., Yoon K. W. Effect of icodextrin dialysis solution on body weight and fat accumulation over time in CAPD patients. Nephrol. Dial. Transplant. 2010; 25 (2): 593-599.
  33. Gallieni M., Musetti C., Granata A. et al. Metabolic consequences of peritoneal dialysis treatment. Panminerva Med. 2009; 51 (3): 175-185.
  34. Johnson D. W., Armstrong K., Campbell S. B. et al. Metabolic syndrome in severe chronic kidney disease: prevalence, predictors, prognostic significance and effects of risk factor modification. Nephrology (Carlton) 2007; 12 (4): 391-398.
  35. Szeto C. C., Chow K. M., Kwan В. С. et al. New-onset hyperglycemia in nondiabetic Chinese patients started on peritoneal dialysis. Am. J. Kidney Dis. 2007; 49 (4): 524-532.
  36. Szeto C. C., Chow K. M, Leung С. В. et al. Increased subcutaneous insulin requirements in diabetic patients recently commenced on peritoneal dialysis. Nephrol. Dial. Transplant. 2007; 22 (6): 1697-1702.
  37. Babazono Т., Nakamoto H., Kasai K. et al. Effects of icodextrin on glycemic and lipid profiles in diabetic patients undergoing peritoneal dialysis. Am. J. Nephrol. 2007; 27 (4): 409-415.
  38. Paniagua R., Ventura M. D., Avila-Däz M. et al. Icodextrin improves metabolic and fluid management in high and high-average transport diabetic patients. Perit. Dial. Int. 2009; 29 (4): 422-432.
  39. Lin S. H., Lin Y. F., Kuo S. W. et al. Rosiglitazone improves glucose metabolism in nondiabetic uremic patients on CAPD. Am. J. Kidney Dis. 2003; 42 (4): 774-780.
  40. Wong T. Y., Szeto С. С., Chow K. М. et al. Rosiglitazone reduces insulin requirement and C-reactive protein levels in type 2 diabetic patients receiving peritoneal dialysis. Am. J. Kidney Dis. 2005; 46 (4): 713-719.
  41. van Hooland S., Boey O., van der Niepen P. et al. Effect of short-term rosiglitazone therapy in peritoneal dialysis patients. Perit. Dial. Int. 2009; 29 (1): 108-111.
  42. Dasgupta M. K. Strategies for managing diabetic patients on peritoneal dialysis. Adv. Perit. Dial. 2004; 20: 200-202.
  43. Mehmet S., Quan G., Thomas S., Goldsmith D. Important causes of hypoglycaemia in patients with diabetes on peritoneal dialysis. Diabet. Med. 2001; 18 (8): 679-682.
  44. Williams J. D., Craig K. J., Topley N. et al. Peritoneal Biopsy Study Group. Morphologic changes in the peritoneal membrane of patients with renal disease. J. Am. Soc. Nephrol. 2002; 13: 470-479.
  45. Stoenoiu M. S., De Vriese A. S., Brouet A. et al. Experimental diabetes induces functional and structural changes in the peritoneum. Kidney Int. 2002: 62 (2): 668-678.
  46. De Vriese A. S., Flyvbjerg A., Mortier S. et al. Inhibition of the interaction of AGE-RAGE prevents hyperglycemia-induced fibrosis of the peritoneal membrane. J. Am. Soc. Nephrol. 2003; 14 (8): 2109-2118.
  47. Selgas R., Diez J. J., Munoz J. et al. Comparative study of two different routes for insulin administration in CAPD diabetic patients. A multicenter study. Adv. Perit. Dial. 1989; 5: 181- 184.
  48. Tzamaloukas A. H., Oreopoulos D. G. Subcutaneous versus intraperitoneal insulin in the management of diabetics on CAPD: a review. Adv. Perit. Dial. 1991; 7: 81-85.
  49. Nevalainen P., Lahtela J. Т., Mustonen J., Pasternack A. The influence of peritoneal dialysis and the use of subcutaneous and intraperitoneal insulin on glucose metabolism and serum lipids in type 1 diabetic patients. Nephrol. Dial. Transplant. 1997; 12 (1): 145-150.
  50. Quellhorst E. Insulin therapy during peritoneal dialysis: pros and cons of various forms of administration. J. Am. Soc. Nephrol. 2002; 13 (Suppl. 1): S92-S96.
  51. Wideroe Т. E., Dahl K. J., Smeby L. С et al. Pharmacokinetics of transperitoneal insulin transport. Nephron 1996; 74 (2): 283-290.
  52. Wanless I. R., Bargman J. M., Oreopoulos D. G. et al. Subcapsular steatonecrosis in response to peritoneal insulin delivery: a clue to the pathogenesis of steatonecrosis in obesity. Mod. Pathol. 1989; 2: 69-74.
  53. Torun D., Oguzkurt L., Sezer S. et al. Hepatic subcapsular steatosis as a complication associated with intraperitoneal insulin treatment in diabetic peritoneal dialysis patients. Perit. Dial. Int. 2005; 25 (6): 596-600.
  54. Nevalainen P. I., Kallio Т., Lahtela J. T. et al. High peritoneal permeability predisposes to hepatic steatosis in diabetic continuous ambulatory peritoneal dialysis patients receiving intraperitoneal insulin. Perit. Dial. Int. 2000; 20 (6): 637-642.
  55. Demir S., Torun D., Tokmak N. et al. Resolution of hepatic subcapsular steatosis after discontinuation of CAPD. Nephrol. Dial. Transplant. 2007; 22 (4): 1247-1249.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2011 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru

 

 © 2018-2021 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies